Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

The American Review of Respiratory Disease
W E RegelmannC C Clawson

Abstract

We evaluated patients with cystic fibrosis (CF) and moderate obstructive lung disease in pulmonary exacerbation in a double-blind placebo-controlled trial to determine the contribution of antibiotic-mediated reduction in sputum bacterial density to clinical improvement. For the first 4 days of study, all patients received bronchodilating aerosols and chest physiotherapy but no antibiotics. During this time, the patients showed significant improvement in mean FVC, FEV1, and maximal midexpiratory flow rate (FEF25-75). In 12 of 13 trials, the patients showed no significant increases in the density of Pseudomonas aeruginosa during these first 4 days. In these 12 trials, the patients were stratified by their initial FVC and randomized to receive either parenteral tobramycin and ticarcillin (n = 7) or placebo (n = 5), in addition to continued aerosol and chest physiotherapy. In the remaining trial, the patient had a significant rise in the density of P. aeruginosa and was assigned to the antibiotic group. During the next 14 days of therapy, the antibiotic group showed significantly (p less than 0.01) greater reductions in log10 colony-forming units (cfu) of P. aeruginosa per gram of sputum and greater increases in FVC, FEV1, and FEF2...Continue Reading

Citations

Sep 3, 2002·Pediatric Pulmonology·Nancy L HordvikJohn L Colombo
Oct 1, 1995·Pediatric Pulmonology·C A FriesenC C Roberts
Jan 1, 1994·Lung·M R ByeL M Quittell
Apr 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M LeBel
Apr 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J L GaillardP Scheinmann
Jan 13, 2006·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B BalkeS Häussler
Sep 1, 1992·International Journal of Antimicrobial Agents·N Høiby
Feb 28, 2001·Microbes and Infection·N HøibyA Kharazmi
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·J R W Govan
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Niels Høiby
Jul 18, 1996·The New England Journal of Medicine·B W Ramsey
Aug 1, 1996·The Pediatric Infectious Disease Journal·N HøibyC Koch
Jan 1, 1997·The Pediatric Infectious Disease Journal·A Smith
Nov 26, 1999·Current Opinion in Pulmonary Medicine·P M Beringer
Oct 10, 2003·Current Opinion in Pulmonary Medicine·Robert N Chernish, Shawn D Aaron
Feb 1, 1992·Journal of Paediatrics and Child Health·K Grimwood
Apr 14, 1999·Australian and New Zealand Journal of Medicine·R L Henry
Apr 14, 1999·Australian and New Zealand Journal of Medicine·J M WolterJ G McCormack
Mar 18, 2000·Antimicrobial Agents and Chemotherapy·P M BeringerB J Shapiro
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·Niels BaggeNiels Høiby
Apr 5, 2002·Clinical Microbiology Reviews·Jeffrey B LyczakGerald B Pier
Mar 23, 1999·Archives of Disease in Childhood·S P Conway
Mar 23, 1999·Archives of Disease in Childhood·M Sood, I W Booth
Mar 28, 2007·Thorax·Christopher H Goss, Jane L Burns
Nov 14, 1997·American Journal of Respiratory and Critical Care Medicine·H BisgaardC Koch
Apr 14, 2000·American Journal of Respiratory and Critical Care Medicine·S D AaronN E Macdonald
Sep 16, 2000·American Journal of Respiratory and Critical Care Medicine·C E MillaA Moran
Dec 14, 2002·American Journal of Respiratory and Critical Care Medicine·Ronald L GibsonUNKNOWN Cystic Fibrosis Therapeutics Development Network Study Group
Oct 14, 2003·American Journal of Respiratory and Critical Care Medicine·Ronald L GibsonBonnie W Ramsey
Sep 13, 2003·American Journal of Respiratory and Critical Care Medicine·Claudia L OrdoñezMoira L Aitken
Dec 13, 2003·American Journal of Respiratory and Critical Care Medicine·Shawn D AaronFrancis Chan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.